GlassScriptPhysician profile
Khaja G Mohsin
NPI 1730162108
$4,574.18
in general payments reported to CMS, 2019-2025
28 companies · $1,367 in 2025
The $1,367 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $463 · 2021: $767 · 2022: $108 · 2023: $648 · 2024: $926 · 2025: $1,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,942.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,644.02 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $279.78 | 2020-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $199.19 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $134.65 | 2023-2025 | |
| Lilly USA, LLC | $131.00 | 2020-2025 | Mounjaro, Jardiance |
| Abbvie INC. | $126.81 | 2020-2021 | |
| Global Blood Therapeutics, INC. | $108.44 | 2020-2021 | |
| Glaxosmithkline, LLC. | $99.84 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $93.60 | 2021 | |
| Optos, INC. | $89.17 | 2021 | |
| Pfizer INC. | $82.46 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.21 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $71.25 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $62.82 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.87 | 2021-2025 | Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $45.38 | 2019-2021 | |
| Abbott Laboratories | $42.81 | 2024-2025 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $37.23 | 2020-2021 | |
| Dexcom, INC. | $35.80 | 2021 | |
| Axsome Therapeutics, INC. | $26.01 | 2025 | Symbravo |
| Optinose US, INC. | $22.22 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.90 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.29 | 2021 | |
| Amgen INC. | $20.20 | 2023 | Otezla, Repatha |
| Azurity Pharmaceuticals, INC. | $16.06 | 2025 | Edarbi |
| Cmp Pharma, INC. | $13.46 | 2021 | |
| Esperion Therapeutics, INC. | $13.29 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaja Mohsin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.